Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy

Journal of Cutaneous Pathology

Volumn 44, Issue 4, 2017, Pages 381-384

  Vivar, Karina L ^a   Deschaine, Maria ^b   Messina, Jane ^b,c   Divine, Jennifer M ^a   Rabionet, Alejandro ^a   Patel, Nishit ^a   Harrington, Michael A ^a   Seminario Vidal, Lucia ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

adverse drug reaction; drug rash; nivolumab; programmed cell death receptor 1 antibodies; toxic epidermal necrolysis

Indexed keywords

MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

CASE REPORT; CD8+ T LYMPHOCYTE; FATALITY; FEMALE; HUMAN; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; STEVENS-JOHNSON SYNDROME;

ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; FATAL OUTCOME; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; STEVENS-JOHNSON SYNDROME;

EID: 85010465838     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12876     Document Type: Article

References (15)

1. Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Euro J Cancer. 2016;60:12–25.
2. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Euro J Cancer. 2016;60:190–209.
3. Totonchy MB, Ezaldein HH, Ko CJ, Choi JN. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol. 2016;152:590–592.
4. Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 inhibitors and anti-programed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152(10):1128–1136.
5. Eigentler TK, Hassel J, Berking C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18.
6. Friedman CF, Proverbs-Singh TA. Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors; JAMA Oncol. 2016;2(10):1346–1353.
7. Dong H, Chen X. Immunoregulatory role of B7-H1 in chronicity of inflammatory response. Cell Mol Immunol. 2006;3:179–187.
8. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
9. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.
10. Youngnak-Piboonratanakit P, Tsushima F, Otsuki N, et al. The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. Immunol Lett. 2004;94:215–222.
11. Zhang J, Tan YQ, Wei MH, et al. TLR4-induced B7-H1 on keratinocytes negatively regulates CD4(+) T cells and CD8(+) T cells responses in oral lichen planus. Exp Dermatol. 2016. doi: 10.1111/exd.13244. [Epub ahead of print]
12. Okiyama N, Katz SI. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J Autoimmun. 2014;53:1–9.
13. Nayar N, Briscoe K, Fernandez Penas P. Toxic epidermal necrolysis-like reaction with severe cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother. 2016;39:149–152.
14. Lee HY, Dunant A, Sekula P, et al. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol. 2012;167:555–562.
15. Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22:4023–4029.